Royal Philips (NYSE:PHG) said yesterday it launched an all-in-one breast assessment solution designed for use with its Epiq and Affiniti ultrasound systems.
The newly launched solution, which has received CE Mark approval in the European Union and FDA 510(k) clearance in the US, is intended for the assessment, monitoring and treatment of breast diseases, the Amsterdam-based company said.
“Ultrasound plays an increasingly important role in breast cancer screening and assessment, helping to detect lesions that mammography alone may not find. Philips is committed to developing the tools clinicians need to deliver the best care for their patients. Our integrated ultrasound solution for breast assessment delivers high-quality imaging enhanced by anatomical intelligence for results clinicians can trust,” Philips ultrasound general imaging biz lead Jeff Cohen said in a prepared statement.
Philips said that the solution is intended to reduce total exam time and the need for room or equipment changes during exams, as well as reducing the number of appointments for patients undergoing breast exams.
“The best way to increase the survival rate from breast cancer is to detect it early. For women with dense breasts, ultrasound can be very helpful in detecting masses not easily seen on the mammogram. I have been impressed by Philips’ continued investment and innovation in developing breast assessment solutions, so that I can provide optimal care for my patients,” Dr. Marcela Böhm-Vélez of Pittsburgh, Penn.’s Weinstein Imaging Associates said in a press release.
Earlier this week, Philips said that it won FDA 510(k) clearance for its IntelliVue GuardianSoftware mobile client application, designed to allow clinicians to view patient vital signs and receive early warning scores on mobile devices.
